170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA
Provides Business Update and Reports Full Year 2025 Financial Results
Termination of Material Definitive Agreement - Vaxart, Inc.
Provides Business Update and Reports Third Quarter 2025 Financial Results
Enters Exclusive License Agreement for Novel Oral COVID-19 Vaccine Program
Reg. FD
Other Events
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Announces Adjournment of Special Meeting of Stockholders
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Additional Proxy Soliciting Materials
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload